Compare Stocks: ZURA, COAG, ANAB, and INBX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$48.53 -0.2%	$55.04	$19.65 ▼ $72.36	$1.45B	0.76	693,818 shs	441,119 shs
COAG Hemab Therapeutics	$31.11 +0.2%	$44.44	$23.00 ▼ $55.42	$1.45B	N/A	378,903 shs	354,147 shs
INBX Inhibrx Biosciences	$96.99 -1.0%	$102.78	$28.16 ▼ $155.29	$1.43B	3.82	317,842 shs	201,446 shs
ZURA Zura Bio	$4.11 -0.7%	$5.35	$3.15 ▼ $7.44	$393.86M	0.01	1.02 million shs	2.95 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	-3.24%	-5.94%	-12.03%	-23.32%	+52.11%
COAG Hemab Therapeutics	+0.71%	-13.05%	-29.44%	+0.19%	+3,105,999,900.00%
INBX Inhibrx Biosciences	-2.15%	-2.46%	-21.44%	+0.36%	+188.20%
ZURA Zura Bio	-0.48%	-0.48%	-26.73%	-19.92%	+2.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$48.53 -0.2%	$55.04	$19.65 ▼ $72.36	$1.45B	0.76	693,818 shs	441,119 shs
COAG Hemab Therapeutics	$31.11 +0.2%	$44.44	$23.00 ▼ $55.42	$1.45B	N/A	378,903 shs	354,147 shs
INBX Inhibrx Biosciences	$96.99 -1.0%	$102.78	$28.16 ▼ $155.29	$1.43B	3.82	317,842 shs	201,446 shs
ZURA Zura Bio	$4.11 -0.7%	$5.35	$3.15 ▼ $7.44	$393.86M	0.01	1.02 million shs	2.95 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	-3.24%	-5.94%	-12.03%	-23.32%	+52.11%
COAG Hemab Therapeutics	+0.71%	-13.05%	-29.44%	+0.19%	+3,105,999,900.00%
INBX Inhibrx Biosciences	-2.15%	-2.46%	-21.44%	+0.36%	+188.20%
ZURA Zura Bio	-0.48%	-0.48%	-26.73%	-19.92%	+2.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.71	Moderate Buy	$77.79	60.18% Upside
COAG Hemab Therapeutics	2.57	Moderate Buy	$51.40	66.50% Upside
INBX Inhibrx Biosciences	2.50	Moderate Buy	$197.50	102.31% Upside
ZURA Zura Bio	2.86	Moderate Buy	$17.00	315.14% Upside

Current Analyst Ratings Breakdown

Latest ZURA, COAG, ANAB, and INBX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	ANAB AnaptysBio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$70.00 ➝ $60.00
9/25/2026	COAG Hemab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
9/23/2026	ANAB AnaptysBio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$90.00 ➝ $81.00
9/22/2026	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$95.00
9/22/2026	ANAB AnaptysBio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/18/2026	INBX Inhibrx Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
9/11/2026	INBX Inhibrx Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/31/2026	ANAB AnaptysBio	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$78.00
8/27/2026	INBX Inhibrx Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
8/25/2026	ANAB AnaptysBio	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$75.00 ➝ $70.00
8/25/2026	ANAB AnaptysBio	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold	$70.00

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$234.60M	6.19	N/A	N/A	$1.34 per share	36.24
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	$1.30M	1,105.37	N/A	N/A	$0.55 per share	177.49
ZURA Zura Bio	N/A	N/A	N/A	N/A	$1.38 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$13.23M	$5.37	9.07	40.81	N/A	82.37%	112.00%	2.20%	11/3/2026 (Estimated)
COAG Hemab Therapeutics	N/A	-$24.78	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	-$140.05M	-$8.88	N/A	N/A	N/A	N/A	-563.90%	-83.48%	11/13/2026 (Estimated)
ZURA Zura Bio	-$99.35M	-$1.13	N/A	N/A	N/A	N/A	-56.13%	-50.15%	11/12/2026 (Estimated)

Latest ZURA, COAG, ANAB, and INBX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/21/2026	Q2 2026	ANAB AnaptysBio	-$0.4650	$5.11	+$5.5750	$5.11	$14.06 million	$27.49 million
8/13/2026	Q2 2026	INBX Inhibrx Biosciences	-$2.28	-$2.34	-$0.06	-$2.34	N/A	N/A
8/11/2026	Q2 2026	COAG Hemab Therapeutics	-$0.63	-$0.80	-$0.17	-$0.80	N/A	N/A
8/11/2026	Q2 2026	ZURA Zura Bio	-$0.1913	-$0.21	-$0.0187	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	7.58	7.58
COAG Hemab Therapeutics	N/A	35.85	35.85
INBX Inhibrx Biosciences	N/A	5.07	5.07
ZURA Zura Bio	N/A	12.90	12.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
COAG Hemab Therapeutics	N/A
INBX Inhibrx Biosciences	82.46%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	31.50%
COAG Hemab Therapeutics	N/A
INBX Inhibrx Biosciences	18.26%
ZURA Zura Bio	12.37%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	104	29.90 million	20.48 million	Optionable
COAG Hemab Therapeutics	59	46.71 million	N/A	N/A
INBX Inhibrx Biosciences	110	14.72 million	12.03 million	Optionable
ZURA Zura Bio	40	95.83 million	83.98 million	Optionable

ZURA, COAG, ANAB, and INBX Headlines

Recent News About These Companies

Zura Bio stock enters a key trial data phase

September 29 at 12:41 AM | ad-hoc-news.deA

Zura Bio stock extends multi-month rally on strong pipeline expectations

September 20, 2026 | ad-hoc-news.deA

Zura Bio Limited Class A Ordinary Shares

September 19, 2026 | livemint.com

Zura Bio Limited (ZURA) Latest Press Releases & Corporate News - Yahoo Finance

September 17, 2026 | finance.yahoo.com

Zura Bio (ZURA) Hits Enrollment Milestones As Losses Widen Sharply

September 11, 2026 | finance.yahoo.com

Zura Bio Limited (NASDAQ:ZURA) Receives Average Rating of "Moderate Buy" from Analysts

September 11, 2026 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Shares Down 7.2% - Time to Sell?

September 9, 2026 | marketbeat.com

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 21, 2026 | businesswire.com

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

August 11, 2026 | businesswire.com

Zura Bio Stock (NASDAQ:ZURAW), Analyst Ratings, Price Targets, Predictions

July 27, 2026 | benzinga.com

William Blair Starts Zura Bio (ZURA) at Outperform

July 14, 2026 | uk.finance.yahoo.com

Licensing a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist

July 9, 2026 | businesswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Qiagen (QGEN) and Zura Bio (ZURA)

July 9, 2026 | theglobeandmail.com

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

June 29, 2026 | finance.yahoo.com

Zura Bio (ZURA) Gets a Buy from Oppenheimer

June 13, 2026 | theglobeandmail.com

Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation

June 3, 2026 | finance.yahoo.com

Zura Bio Announces Board Resignation, Governance Stability Affirmed

May 22, 2026 | tipranks.com

Analysts Are Bullish on These Healthcare Stocks: Silence Therapeutics (SLN), Zura Bio (ZURA)

May 11, 2026 | theglobeandmail.com

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

May 7, 2026 | businesswire.com

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 4, 2026 | businesswire.com

Zura Bio Limited Class A

April 24, 2026 | edition.cnn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ZURA, COAG, ANAB, and INBX Company Descriptions

AnaptysBio NASDAQ:ANAB

$48.53 -0.10 (-0.21%)

Closing price 04:00 PM Eastern

Extended Trading

$48.58 +0.05 (+0.09%)

As of 07:30 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Hemab Therapeutics NASDAQ:COAG

$31.11 +0.05 (+0.16%)

As of 04:00 PM Eastern

We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. We estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets, including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. We aim to establish the industry’s leading coagulation franchise through the execution of our “Hemab 2x3 by 2030” strategic roadmap, which is designed to build a franchise consisting of 2 commercial medicines, 2 new late-stage clinical programs, and 2 new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. Our principal executive offices are located in Cambridge, MA.

Inhibrx Biosciences NASDAQ:INBX

$96.99 -0.94 (-0.96%)

Closing price 04:00 PM Eastern

Extended Trading

$97.10 +0.12 (+0.12%)

As of 07:30 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Zura Bio NASDAQ:ZURA

$4.11 -0.03 (-0.72%)

Closing price 04:00 PM Eastern

Extended Trading

$4.14 +0.03 (+0.71%)

As of 07:56 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZURA, COAG, ANAB, and INBX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZURA, COAG, ANAB, and INBX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZURA, COAG, ANAB, and INBX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZURA, COAG, ANAB, and INBX Company Descriptions

AnaptysBio NASDAQ:ANAB

Hemab Therapeutics NASDAQ:COAG

Inhibrx Biosciences NASDAQ:INBX

Zura Bio NASDAQ:ZURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZURA, COAG, ANAB, and INBX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZURA, COAG, ANAB, and INBX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZURA, COAG, ANAB, and INBX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZURA, COAG, ANAB, and INBX Company Descriptions

AnaptysBio NASDAQ:ANAB

Hemab Therapeutics NASDAQ:COAG

Inhibrx Biosciences NASDAQ:INBX

Zura Bio NASDAQ:ZURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools